// App-Quantinova.ai

3018 : Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1.

Researchers

Presenter

  • Aung Naing

Principal Investigators

  • Jeffrey R. Infante

  • Deborah Jean Lee Wong

  • Karen A. Autio

  • Patrick Alexander Ott

  • Gerald Steven Falchook

  • Manish R. Patel

  • Shubham Pant

  • Amita Patnaik

  • John B Mumm

  • Melinda Whiteside

  • Ivan H Chan

  • Johanna C. Bendell

  • Todd Michael Bauer

  • Filip Janku

  • Rivka R Colen

  • Nizar M. Tannir

  • Peter Van Vlasselaer

  • Martin Oft

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • START Center for Cancer Care, San Antonio, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Ronald Reagan UCLA Medical Center, Los Angeles, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • Sarah Cannon Research Institute, Denver, CO

  • Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL

  • Oklahoma University Health Science Center, Edmond, OK

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • ARMO BioSciences, Redwood City, CA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Non Small Cell Lung cancer

Biomarkers

  • Cluster of differentiation 8A

  • Interleukin 10

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • AM-0010

  • Interleukin-10

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02009449

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved